Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study
Our findings suggest that HER2-low breast cancer is associated with improved survival outcomes compared to HER2-zero breast cancer. HER2-low breast cancer exhibits different survival outcomes across different HR subgroups. These findings may guide future biomarker-driven treatment strategies in HER2-negative breast cancer.
Authors
- Pengfei Qian (ORCID: https://orcid.org/0000-0001-7320-5777)
- Yu Sun (ORCID: https://orcid.org/0000-0003-3938-7057)
- Gordon Li (ORCID: https://orcid.org/0000-0001-8372-0676)
- Yi Zeng (ORCID: https://orcid.org/0009-0005-6225-0632)
Institutions
- Huizhou Central People's Hospital (CN)
- Guangzhou Medical University (CN)
- Huizhou University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1186/s12957-025-03962-4
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05